Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a, Multi-Center, Open Label, Randomized, Feasibility/Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Subjects Undergoing Elective PCI [percutaneous coronary intervention] After Pretreatment With Clopidogrel and Aspirin.

X
Trial Profile

Phase 2a, Multi-Center, Open Label, Randomized, Feasibility/Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Subjects Undergoing Elective PCI [percutaneous coronary intervention] After Pretreatment With Clopidogrel and Aspirin.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anivamersen-pegnivacogin (Primary) ; Heparin
  • Indications Coronary artery disease; Coronary stent thrombosis; Coronary thrombosis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms REVERSAL-PCI
  • Sponsors Regado Biosciences
  • Most Recent Events

    • 26 Jul 2010 Results have been published in Circulation, according to a Regado Biosciences media release.
    • 15 Mar 2010 Results were presented at the 59th Annual Scientific Session of the American College of Cardiology.
    • 31 Aug 2009 Positive results from this trial is the basis for proceeding to the next phase (IIb) of development (see trial profile 700046757).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top